. In contrast to obesity, few genetic variants underlying these clinical conditions have been reported 8, 9 . We previously showed that hemizygosity of a 600-kilobase (kb) region on the short arm of chromosome 16 causes a highly penetrant form of obesity that is often associated with hyperphagia and intellectual disabilities 10 . Here we show that the corresponding reciprocal duplication is associated with being underweight. We identified 138 duplication carriers (including 132 novel cases and 108 unrelated carriers) from individuals clinically referred for developmental or intellectual disabilities (DD/ID) or psychiatric disorders, or recruited from populationbased cohorts. These carriers show significantly reduced postnatal weight and BMI. Half of the boys younger than five years are underweight with a probable diagnosis of failure to thrive, whereas adult duplication carriers have an 8.3-fold increased risk of being clinically underweight. We observe a trend towards increased severity in males, as well as a depletion of male carriers among non-medically ascertained cases. These features are associated with an unusually high frequency of selective and restrictive eating behaviours and a significant reduction in head circumference. Each of the observed phenotypes is the converse of one reported in carriers of deletions at this locus. The phenotypes correlate with changes in transcript levels for genes mapping within the duplication but not in flanking regions. The reciprocal impact of these 16p11.2 copy-number variants indicates that severe obesity and being underweight could have mirror aetiologies, possibly through contrasting effects on energy balance.
Copy-number variants (CNVs) at the 16p11.2 locus have been associated with cognitive disorders including autism (deletions) and schizophrenia (duplications) [11] [12] [13] , conditions that have been suggested to lie at opposite ends of a single spectrum of psychiatric phenotypes 14 . We and others have reported that a deletion of this region spanning 28 genes (Supplementary Table 1 ) increases the risk of morbid obesity 43-fold (Supplementary Fig. 1 ) 10, 15 . We hypothesized that the reciprocal duplication, with its resulting increase in gene dosage, may influence BMI in a converse manner. The duplication was identified in 73 out of 31,424 patients with DD/ID, a frequency consistent with previous reports 13 ( Table 1) . Four additional cases were identified among 1,080 patients affected by bipolar disease or schizophrenia. Compared to its prevalence in seven European population-based genome-wide association study (GWAS) cohorts [16] [17] [18] (31 out of 58,635 individuals), the duplication was significantly more frequent in both the DD/ID cohorts (P 5 4.23 3 10 213 ; odds ratio 5 4.4, 95% confidence interval 5 2.9-6.9) and the psychiatric cohorts (P 5 3.6 3 10
23
; odds ratio 5 7.0, 95% confidence interval 5 1. 8-19.9) (Table 1) , strengthening previous reports of similar associations 12, 13 . Our data do not support a two-hit model 19 for the effects of 16p11.2 duplications or deletions (Supplementary Text and Supplementary Table 2) .
We compared available data on weight, height and BMI for 106 independent duplication carriers (including published cases) to data for reference populations matched for gender, age and geographical location ( Table 2, Methods and Supplementary Tables 3 and 4 ). The duplication was strongly associated with lower weight (mean Z-score 20.56; P 5 4.4 3 10
24
) and lower BMI (mean Z-score 20.47; P 5 2.0 3 10 23 ) ( Table 2 and Supplementary Table 5 ). Birth parameters (n 5 48) were normal, indicating a postnatal effect. Adults carrying the duplication had a relative risk of being clinically underweight (BMI ,18.5) of 8.3 (95% confidence interval 5 4.4-15.9, P 5 1.53 3 10 210 ) (see Methods). Concordantly, none of the 3,544 patients in our obesity cohorts 10, 15 carried the duplication (Table 1) . To investigate these associations further, we carried out separate analyses of carrier patients (DD/ID and psychiatric) and non-medically ascertained carriers (population-based cohorts, plus 11 transmitting parents and three other affected first-degree relatives for whom data were available) ( Table 2) . Each category had significantly lower weight and BMI, with similar effect sizes. However, the proportion of underweight cases (BMI # 22 s.d.) was higher in the first group than in the second group (17 out of 76 compared to 2 out of 40; P 5 0.017). Note that the impact of the duplication on underweight status might be underestimated here owing to prescription of antipsychotic treatments that are often associated with weight gain 20 (Supplementary Table 6 ). Having demonstrated an association of the duplication with being underweight, we investigated the implications of gender for the resulting phenotypes ( Fig. 1, Supplementary Fig. 2 and Supplementary Table 7 ). In DD/ID patients, the impact of the duplication on being underweight is stronger in males; the effect in females is in the same direction, but is smaller and not statistically significant (Table 2) . A similar and significant difference (P 5 0.0168) was observed in adult carriers (all groups combined): the relative risk of being underweight for males is 23.2 (95% confidence interval 5 9.1-59.3, P 5 4.6 3 10 211 ); for females it is only 4.7 (95% confidence interval 5 1.9-11.8, P 5 9.9 3 10 24 ). A gender bias was also observed in the ascertainment of DD/ID duplication carriers, in which we have an excess of males (51 males:33 females, P 5 0.044). By contrast, carriers from the general population showed a strong overrepresentation of females (10 males:21 females, P 5 0.035) (Supplementary Text). A similar bias was observed among transmitting parents (7 males:23 females, P 5 5.53 3 10
). Thus, there is an overrepresentation of males in the medically ascertained group, and a depletion in the non-medically ascertained one. We suggest that males may be more likely than females to present severe phenotypes, and that this may account for the gender bias because severely affected males may be less likely to be recruited to adult population cohorts or to be reproductively successful.
As previously reported 21 , the duplication was also associated with reduced head circumference (mean Z-score 20.89; P 5 7.8 3 10 26 ) (Fig. 1) , 26.7% presenting with microcephaly (head circumference # 22 s.d.), whereas carriers of the reciprocal deletion had an increased head circumference (mean Z-score 10.57; P 5 1.79 3 10
25
) (Supplementary Fig. 3 and Supplementary Table 8) : an additional instance of a mirror phenotype associated with reciprocal changes in copy number at this locus. Notably, head circumference Z-scores correlate positively with those of BMI in carriers of both the duplication (rho 5 0.37; P 5 2.65 3 10
23
) and the deletion (rho 5 0.42; P 5 1.9 3 10 25 ) (Supplementary Methods). This indicates that head circumference and BMI may be regulated by a common pathway, or that a causal relationship exists between these two traits in these patients. Alternatively, the two phenotypes may arise from distinct genes and pathways. A full list of malformations and secondary phenotypes reported in duplication carriers ascertained for DD/ID is available in Supplementary Table 9 .
In view of the importance of modified eating behaviours in obesity and being underweight, the clinical reports of duplication carriers were screened for evidence of such modified behaviours. In 11 out of 77 clinically ascertained cases, clinicians had spontaneously reported low food intake and selective and restrictive eating behaviour, again mirroring one of the phenotypes-hyperphagia-seen in deletion carriers 10 (Supplementary Table 6 ) and indicating that the duplication may increase the risk of eating disorders. Consequently, we carried out multiplex ligation-dependent probe amplification (MLPA, Supplementary Table 10 ) to screen for 16p11.2 rearrangements in 441 patients diagnosed with eating disorders, including anorexia nervosa, bulimia and binge eating disorder (Table 1 and Supplementary Text). No duplications of the entire region were identified, but one out of 109 anorexia nervosa patients carried an atypical 136-kb duplication that encompasses the sialophorin (SPN) and quinolinate phosphoribosyltransferase (QPRT) genes ( Supplementary Fig. 4 ). This single, smaller duplication does not allow us to draw any firm conclusions, but together with other atypical rearrangements, it may, in the future, be essential for establishing the roles of the 28 genes within the region.
Large genomic structural variants are known to affect the expression of genes not only within the affected region but also at a distance [22] [23] [24] [25] . Therefore, it is possible that the phenotypes observed in 16p11.2 deletion and duplication individuals are due to effects on the expression of genes mapping outside the rearranged interval, rather than to gene dosage within the 600-kb deletion or duplication. We measured CI, Confidence interval; ADHD, attention-deficit hyperactivity disorder. *Not a disease-specific cohort. Detailed distribution is provided in the online methods. {Fisher's exact test, compared to the combined frequency in general population groups. {There was no overlap between these 3 cohorts. 1Atypical duplication (see Supplementary Fig. 5 ). I Total number of parental pairs tested for duplication/deletion. 13 out of 43 duplications and 27 out of 62 deletion cases were de novo. 
26
The available BMI, weight and height data for duplication carriers were transformed to Z-scores using gender-and age-matched reference populations, and one-tailed t-tests were carried out to determine whether the mean Z-scores deviated from zero. Significant differences were identified by reference to cutoffs controlling the false discovery rate at 5% (see Methods): BMI, 0.022; weight, 0.032; height, 0.025. Significant results are indicated in bold. Data were not available for all subjects. *Relatives of probands were excluded as required, to avoid including more than one member of the same family in a single analysis. {Including 24 cases from the literature (Supplementary Table 3) . {Population-based cases and first-degree relatives of probands.
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relative transcript levels of 27 genes mapping within or near to the rearrangement, using lymphoblastoid cell lines (Supplementary  Tables 1 and 11 ): six from deletion carriers, five from duplication carriers and ten from gender-and age-matched controls (Supplementary Table 12 ). Expression levels correlated positively with gene dosage for all genes in the CNV region ( Fig. 2) , consistent with published partial results from adipose tissue 10 . Mean relative transcript levels in deletion and duplication carriers were, respectively, 67% and 214% of the levels measured in controls (Supplementary Table 13 ). Although genes proximal (centromeric) to the rearrangement interval showed no significant variation in relative transcript levels between patients and controls ( Fig. 2 ), distal (telomeric) genes showed a marked alteration in relative expression. However, their expression levels, including that of SH2B1 (for which gene dosage and a nearby single nucleotide polymorphism (SNP) have been associated with obesity 15, 26 ), were similarly upregulated in cell lines of both deletion and duplication carriers, showing no apparent correlation between transcript level and either copy number or phenotype (Fig. 2) . Although lymphoblastoid cells may not recapitulate obesity-relevant tissues, previous experiments have shown a high degree of correlation between expression levels in different tissues and cell lines 22 , indicating that the same pathways may be similarly disrupted in different cell lineages. Thus, any involvement of these distal genes in the control of BMI in these subjects seems unlikely.
Our study demonstrates the power of very large screens (.95,000 samples: to our knowledge the largest of its kind so far) to characterize the clinical and molecular correlates of a rare functional genomic variant. We demonstrate unambiguously that carrying the 16p11.2 duplication confers a high risk of being clinically underweight, and show that reciprocal changes in gene dosage at this locus result in several mirror phenotypes. As in the schizophrenia/autism 14 and microcephaly/ macrocephaly 21 dualisms, abnormal eating behaviours, such as hyperphagia and anorexia, could represent opposite pathological manifestations of a common energy-balance mechanism, although the precise relationships between these mirror phenotypes remain to be determined. We speculate that head circumference (which correlates with brain volume 27 ), and thus neuronal circuitry, may affect cognitive function and energy balance in patients with 16p11.2 rearrangements (possibly through eating behaviour). Consistent with this are previous reports that a subgroup of children with microcephaly show a concomitant reduction in weight percentile 28 . Our findings also support the observation that severe overweight and underweight phenotypes correlate with lower cognitive functioning 4, 29 . Thus, abnormal food intake may be a direct result of particular neurodevelopmental disorders. Although it is possible that the 16p11.2 region encodes distinct genes specific for each trait, a more parsimonious hypothesis is that these clinical manifestations of dysfunction of the central nervous system are all secondary to the disruption of a single neurodevelopmental step that is sensitive to gene dosage. Further resolution of this issue may IL4R  CLN3  ATXN2L  SH2B1  LAT  QPRT  MAZ  PRRT2  C16orf53   MVP  CDIPT1  SEZ6L2  KCTD13  TMEM219  TAOK2  HIRIP3  DOC2A  FAM57B  PPP4C  INO80E  YPEL3  GDPD3  MAPK3  CORO1A  SEPT1  ZNF688 between the expression of 27 genes mapping to 16p11.2 in deletion and duplication carriers (red and green, respectively) and in control cell lines (blue). Genes are labelled as telomeric, centromeric or within the rearranged interval (CNV). Dots correspond to the mean group rank and bars indicate the comparison interval. Groups with non-overlapping intervals are significantly different (P-values were adjusted for multiple testing issues using a Bonferroni correction, where the number of tests is the number of pairwise comparisons; the resulting adjusted P-value was less than 0.05).
Male cases
Female cases P = 0.028 P = 0.559 P = 0.377 P = 0.016 P = 0.021 P = 0.003 P = 0.308 P = 0.020 n = 12 n = 7 n = 13 n = 4 n = 12 n = 11 n = 12 n = 14 n = 20 n = 7 n = 13 n = 27 P = 0.306 P = 0.441 P = 0.049 P = 0.015 LETTER RESEARCH require the identification of additional patients with rare atypical rearrangements in this region.
METHODS SUMMARY
Underweight is defined in adults as BMI # 18.5. In individuals younger than 18 years of age, it is defined as a Z-score # 22. Statistics. Two-tailed Fisher's exact test was used to compare frequencies of the rearrangement in patients and controls. Z-scores were computed for all data using gender-, age-and geographically-matched reference populations. One-tailed Student's t-test was performed to test BMI, height, weight and head circumference in duplication carriers for Z-scores of less than zero. We used Kruskal-Wallis tests for differences in gene expression patterns. P-values were adjusted using a Bonferroni correction, considering the number of pairwise comparisons; the resulting adjusted P-value was less than 0.05. The relative risk of being underweight was calculated as the ratio of the fraction of underweight individuals among duplication carriers versus our control group. Discovery of CNVs. Carriers of 16p11.2 duplication and deletion were identified through various procedures: (1) comparative genomic hybridization with Agilent 44K, 60K, 105K, 180K, 244K arrays; (2) Illumina Human317, Human370, HumanHap550, Human610 and 1M BeadChips; (3) Affymetrix 6.0, 500K genotyping arrays; (4) quantitative multiplex PCR of short fluorescent fragments (QMPSF); (5) fluorescent in situ hybridization (FISH); (6) MLPA. CNV analyses of GWAS data were carried out using cnvHap, a moving-window average-intensity procedure, a Gaussian mixture model, circular binary segmentation, QuantiSNP, PennCNV, BeadStudio GT module and Birdseed. At least two independent algorithms were used for each cohort. Expression analyses. Lymphoblastoid cell lines were established from carriers and controls. SYBR Green quantitative PCR was performed to assess relative expression of genes. 
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Study cohorts. For the description of these cohorts, refer to Supplementary Information. CNV detection. Cases ascertained for intellectual disabilities and developmental delay were identified through standard medical diagnostic procedures. CNV analyses of GWAS data were variously carried out using cnvHap 31 ; a moving-window average-intensity procedure; a Gaussian mixture model (Valsesia et al., submitted); circular binary segmentation 32, 33 ; QuantiSNP 34 ; PennCNV 35 ; BeadStudio GT module (Illumina Inc.); and Birdseed 36 (see below). At least two independent algorithms were used for each cohort. Patients referred for intellectual disabilities and developmental delay. All diagnostic procedures (CGH, quantitative PCR and/or quantitative multiplex PCR of short fluorescent fragments) were carried out according to the relevant guidelines of good clinical laboratory practice for the respective countries. All rearrangements in probands were confirmed by a second independent method and karyotyping was performed in all cases to exclude a complex rearrangement. Northern Finland 1966 birth cohort (NFBC). CNV calling has been previously described 10 . In brief, data were normalized using Illumina BeadStudio, then GC effects on ratios were removed by regressing on GC and GC2, and wave effects were removed by fitting a Loess function 37 . CNV analysis was done using cnvHap 31 . All called 16p11.2 duplications were validated by direct analysis of log 2 ratios. Data for each probe were normalized by first subtracting the median value across all samples (so that the distribution of ratios for each probe was centred on zero), and then dividing by the variance across all samples (to correct for variation in the sensitivity of different probes to copy-number variation). All CNV calls were confirmed by MLPA. deCODE genetics. Illumina Human317, Human370, HumanHap550, Human610 and 1M BeadChips were used for CNV analysis. BeadStudio (version 2.0) was used to call genotypes, normalize the signal intensity data and establish the log R ratio (LRR) and B allele frequency (BAF) at every SNP according to standard Illumina protocols. All samples passed a standard SNP-based quality control procedure with a SNP call rate greater than 0.97. PennCNV 35 , a free, open-source tool, was used for detection of CNVs. The input data for PennCNV are LRR, a normalized measure of the total signal intensity for the two alleles of the SNP, and BAF, a normalized measure of the allelic intensity ratio of the two alleles. These values are derived with the help of control genotype clusters (HapMap samples), using the Illumina BeadStudio software. PennCNV employs a hidden Markov model to analyse the LRR and BAF values across the genome. CNV calls are made on the basis of the probability of a given copy state at the current marker, as well as on the probability of observing a copy-state change from the previous marker to the current one. PennCNV uses a built-in correction model for GC content 38 . Cohorte Lausannoise (CoLaus). Data normalization and CNV calling have been previously described 10 . Data normalization included allelic cross-talk calibration 39, 40 , intensity summarization using robust median average, and correction for any PCR amplification bias. Wave effects were corrected by fitting a Loess function 37 . CNV calling was done using a Gaussian mixture model (Valsesia et al., submitted) that fits four components (deletion, copy-neutral, one additional copy and two additional copies) to copy-number ratios. The final copy number at each probe location is determined as the expected (dosage) copy number. The method has been validated by comparing test data sets with results from the CNAT 41 and CBS 32,33 algorithms, and by replicating a subset of CoLaus subjects on Illumina arrays. Only duplications found by both Gaussian mixture model and CBS were considered. Estonian genome center of the University of Tartu (EGCUT). Genotypes were called by BeadStudio software GT module v3.1 or GenomeStudio GT v1.6 (Illumina Inc.). Values for LRR and BAF produced by BeadStudio were formatted for further CNV analysis and break-point mapping with Hidden-Markov-Modelbased softwares QuantiSNP (ver.1.1) 34 and PennCNV 42 or CNVPartition 2.4.4 (Illumina Inc.). All analyses were carried out using the recommended settings, except changing EMiters to 25 and L to 1,000,000 in QuantiSNP. For PennCNV, the Estonian-population-specific SNP allele frequency data was used. All detected duplications were confirmed by quantitative PCR. Study of health in Pomerania (SHIP). Raw intensities were normalized using Affymetrix power tools (Affymetrix); CNV analysis was done using Birdseye from the Birdsuite software package 36 and PennCNV
35
. PennCNV predictions with confidence scores less than 10 were removed. Birdsuite predictions were filtered as in ref. 15 : CNVs were kept if their linkage disequilibrium (LOD) score was .10, length .1 kb, number of probes $5 and size per number of probes ,10,000. Kooperative Gesundheitsforschung in der Region Augsburg (KORA) F3 and F4. Genotyping for KORA F3 was performed using the Affymetrix 500K array set, consisting of two chips (StyI and NspI). The KORA F4 samples were genotyped with the Affymetrix human SNP array 6.0. For both studies, genomic DNA from blood samples was used for analysis. Hybridization of genomic DNA was done in accordance with the manufacturer's standard recommendations. Genotyping was done in the Genome Analysis Centre of the Helmholtz Centre Munich. Genotypes were determined using BRLMM clustering algorithm (Affymetrix 500K array set) and Birdseed2 clustering algorithm (Affymetrix array 6.0). For quality control purposes, we applied a positive control and a negative control DNA every 48 samples (KORA F3) or 96 samples (KORA F4). On the chip level, only subjects with overall genotyping efficiencies of at least 93% were included. In addition, the called gender had to agree with the gender in the KORA study database. After exclusions, 1,644 individuals remained in KORA F3 and 1,814 in KORA F4 for further analysis. MLPA analysis. We used MLPA to determine changes in the copy number of a region of about 2 Mb on chromosome 16p11.2. Briefly, we designed, using hg18, nine probes within the targeted region, one control probe outside the rearranged region and seven control probes targeting unique position in the genome (Supplementary Table 10 ). Assays were performed with MRC-Holland reagents according to the manufacturer's protocol 43 . The analysis of the amplification products was performed by capillary electrophoresis in the DNA Analyser 3730XL and using the GeneMapper software v3.7 (Applied Biosystems). The calculations were performed independently for each experiment: we first normalized the MLPA data to minimize the amount of experimental variation, summing all signal values of each control probe for each sample, and then dividing each signal value of each sample by the sum. The normalized signal values were compared to signal values from all other samples in the same experiment, dividing the normalized signal values by the average calculated from all the samples in the same experiment. The product of this calculation is termed dosage quotient (DQ). A DQ value of less than 0.65 or more than 1.25 was considered as copy-number loss or gain, respectively, as previously described [44] [45] [46] . Custom array-CGH for the short arm of chromosome 16. DNA samples were labelled with Cy3 and cohybridized to custom-made Nimblegen arrays with Cy5-labelled DNA from the CEPH cell line GM12042. These arrays contained 71,000 probes spread across the short arm of chromosome 16 from 22.0 Mb to 32.7 Mb (at a median space of 45 bp between 27.5 Mb and 31.0 Mb), and 1,000 control probes situated in invariable regions of the X chromosome. DNA labelling, hybridization and washing were performed according to Nimblegen protocols. Scanning was performed using an Agilent G2565BA microarray scanner. Image processing, quality control and data extraction were performed using the Nimblescan software v.2.5. Defining underweight. Underweight was defined throughout the study as BMI # 18.5 kg per m 2 in adults and # 22 s.d. in children 30, 47, 48 . Weight, height, BMI and head circumference Z-scores as a function of age. For paediatric cases, weight, height, BMI and head circumference Z-scores were determined for paediatric cases (0-18 years of age) using clinical growth charts specific to the country of origin. Children were ascertained from nine different countries. If charts were only available in percentiles, those measures were transformed into Z-scores using gender-, age-and geographically-matched reference populations (see Statistics).
For the USA and Canada, data from the Center for Disease Control and National Center for Health Statistics (CDC/NCHS) were used to calculate Z-scores 49 . For the French paediatric population, we used French national growth charts 50, 51 . For the Swiss paediatric population, we used Swiss national growth charts 52 . For Dutch participants, Dutch national growth charts were used 53 . For Italian, German, Finnish and Austrian cases (n 5 6), height, weight and BMI Z-scores were estimated using WHO growth charts 54 .
To check for discrepancies generated by the use of different growth charts, height, weight and BMI Z-scores were recalculated using WHO growth charts for all cases under five years of age, regardless of origin (http://www.who.int/ childgrowth/standards/en/54). Z-scores obtained using the WHO data were not significantly different. These growth standards, developed by the World Health Organization multicentre growth reference study, describe normal child growth from birth to 5 years under optimal environmental conditions. These standards can be applied to all children everywhere, regardless of ethnicity, socioeconomic status and type of feeding 55, 56 . If necessary, percentile values were transformed to Z-scores by the inversenormal density function. When growth charts were unavailable, we used reported LMS parameters (median (M), generalized coefficient of variation (S) and skewness (L)) to obtain Z-scores via the formula:
in which X is the observed value.
In adults (.18 years of age), we estimated LMS parameters when these were unavailable from the available sex-, age-and origin-matched Swiss (CoLaus),
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Estonian or French control populations. For cases identified from populationbased cohorts, Z-scores were directly inferred from the cohort. Gene expression. We established lymphoblastoid cell lines from deletion and duplication carriers, as well as from controls (Supplementary Table 12 Table 12 ). SYBR Green real-time quantitative PCR (RT-PCR) was performed as previously described 22, 57 . Briefly, 1 mg of total RNA from lymphoblastoid cell lines was converted to complementary DNA using Superscript VILO (Invitrogen) primed with a mixture of oligo(dT) and random hexamers. Oligos were designed using the PrimerExpress program (Applied Biosystems) with default parameters (Supplementary Table 11 ). Non-intronspanning assays were tested for genomic contamination in standard 6 reverse transcriptase reactions. The amplification efficiency of each primer pair was tested in a cDNA dilution series, as previously described 58 . A full list of genes mapping in the rearranged interval, and exclusion criteria, are presented in Supplementary  Table 1 . All RT-PCR reactions were performed in a 10-ml final volume and triplicates per sample. The setup in a 384-well plate format was performed using a Freedom EVO robot (TECAN) and assays were run in an ABI 7900 sequence detection system (Applied Biosystems) with the following amplification conditions: 50 uC for 2 min, 95 uC for 10 min, and 45 cycles of 95 uC 15 s, then 60 uC for 1 min. A final incubation of 95 uC for 15 s followed by 60 uC for 15 s was carried out to establish a dissociation curve. Each plate included the appropriate normalization genes to control for any variability between plate runs. Raw threshold cycles (Ct) values were obtained using SDS2.4 (Applied Biosystems). To calculate the normalized relative expression ratio of individuals carrying the CNV and of controls, we used Biogazelle qBase Plus software 59 including geNorm 60 . This program identified appropriate normalization genes (EEF1A1, RPL13, GUSB and TBP) having a gene-stability measure of M 5 0.25. We note that one gene, LAT, showed a very high expression profile in one of the duplication samples (DASYL, Supplementary Table 13) , reaching a relative expression value of 27.3 (s.e.m. 5 1.37), compared to an average expression for other duplications of 1.89 (s.e.m. 5 0.51). We cannot exclude that this finding is genuine (and confirmed it in a second experiment), but it was removed from further analyses as an outlier to give a more accurate overview of expression profiles for these genes.
In silico analysis was performed to check for brain, and specifically hypothalamus, expression of genes in the rearranged 16p11.2 interval (Supplementary Table 1 ). This was done using Allen Brain Atlas Resources, available from http://www.brain-map. org. Cases with major neurological signs. Major neurological signs were defined by moderate to severe hypotonia, hypertonia, ataxia, spasticity, hypereflexia, hyporeflexia and/or extra-pyramidal signs, and by the presence of epilepsy. Statistics. Student's t-test: one-tailed t-tests were performed to test whether duplication carriers have Z-score values lower than zero for BMI, height and weight. We found this analysis more suitable than linear regression analysis, correcting for confounding factors such as sex and age, because these anthropometric traits have a highly nonlinear dependence on these factors, as can be observed in control populations.
Kruskal-Wallis test: this was used to test differences in the gene expression pattern between deletion and duplication carriers and control individuals. Because expression values are not necessarily normally distributed, this test is more adequate than a classical one-way analysis of variance. To test pairwise differences, we computed the difference in mean group rank with its 95% confidence interval (as provided by the multcompare function in Matlab). Correction for multiple testing was done using a Bonferroni adjustment.
Multiple testing: we determined false-discovery-rate-based thresholds for association P-values for each phenotype, to correct for multiple testing. For each phenotype, we replaced the observed Z-scores with numbers randomly drawn from a standard normal distribution and performed the same t-tests for the same strata. The procedure was repeated 1,000 times. For various P-value thresholds, we asked how many tests would be declared significant for the null set on average (over the 1,000 random draws). The false discovery rate was estimated as the ratio of this number and the actual number obtained for the observed Z-scores. Thus, we controlled the dependence between nested tests.
Relative risk: among adults, we defined underweight as a BMI ,18.5 (WHO criteria). The estimated relative risk is the ratio of the fraction of underweight individuals among duplication carriers versus our control group. The standard error of log(relative risk) and its significance were calculated as previously described 61 . In our control group (population-based cohorts), the frequency of being underweight is 1.9% (38 males and 148 females out of 9,470). Owing to the fact that being underweight decreases with age in the general population, we resampled our control group to ensure precise age-matching.
